The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10444078" target="_blank" >RIV/00669806:_____/22:10444078 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/22:10444078 RIV/00064190:_____/22:N0000028

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JFeBK1F4R6" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JFeBK1F4R6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2022.020" target="_blank" >10.5507/bp.2022.020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020

Popis výsledku v původním jazyce

Aims. We analyzed the mortality risk and its predictors in patients hospitalized for heart failure (HF). Methods. Patients discharged from hospitalization for acute decompensation of HF in 2010- 2020 and younger than 86 years were followed (n=4097). We assessed the incidence and trends of all-cause death, its main predictors, and the pharmacotherapy recommended at discharge from the hospital. Results. The 30 days all-cause mortality was in discharged patients 3.2%, while 1-year 20.4% and 5-years 55.4%. We observed a modest trend to decreased 1-year mortality risk over time. Any increase of year of hospitalization by one was associated with about 5% lower risk in the fully adjusted model. Regarding predictors of 1-year mortality risk, a positive association was found for age over 65, history of malignancy, and peak brain natriuretic peptide during hospitalization &gt;= 10times higher than normal concentration. In contrast, as protective factors, we identified LDL &gt;= 1.8 mmol/L, treatment with beta-blockers, renin-angiotensin axis blockers, statins, and implanted cardioverter in the same regression model. The ejection fraction category and primary etiology of HF (coronary artery disease vs. others) did not significantly affect the mortality risk in a fully adjusted model. Conclusions. Despite advances in cardiovascular disease management over the last two decades, the prognosis of patients hospitalized for heart failure remained highly unfavorable.

Název v anglickém jazyce

The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020

Popis výsledku anglicky

Aims. We analyzed the mortality risk and its predictors in patients hospitalized for heart failure (HF). Methods. Patients discharged from hospitalization for acute decompensation of HF in 2010- 2020 and younger than 86 years were followed (n=4097). We assessed the incidence and trends of all-cause death, its main predictors, and the pharmacotherapy recommended at discharge from the hospital. Results. The 30 days all-cause mortality was in discharged patients 3.2%, while 1-year 20.4% and 5-years 55.4%. We observed a modest trend to decreased 1-year mortality risk over time. Any increase of year of hospitalization by one was associated with about 5% lower risk in the fully adjusted model. Regarding predictors of 1-year mortality risk, a positive association was found for age over 65, history of malignancy, and peak brain natriuretic peptide during hospitalization &gt;= 10times higher than normal concentration. In contrast, as protective factors, we identified LDL &gt;= 1.8 mmol/L, treatment with beta-blockers, renin-angiotensin axis blockers, statins, and implanted cardioverter in the same regression model. The ejection fraction category and primary etiology of HF (coronary artery disease vs. others) did not significantly affect the mortality risk in a fully adjusted model. Conclusions. Despite advances in cardiovascular disease management over the last two decades, the prognosis of patients hospitalized for heart failure remained highly unfavorable.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Svazek periodika

166

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

10

Strana od-do

312-321

Kód UT WoS článku

000790590300001

EID výsledku v databázi Scopus

2-s2.0-85138142072